Amgen Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.85B | $22.99B | $21.66B | $20.06B | $18.68B | $17.27B | $15.58B | $15.05B |
| Repatha | — | $141.0M | — | — | — | — | — | — |
| EVENITY | — | — | — | — | — | — | — | — |
| Prolia | $1.97B | $1.64B | — | — | — | — | — | — |
| TEPEZZA | — | — | — | — | — | — | — | — |
| KRYSTEXXA | — | — | — | — | — | — | — | — |
| UPLIZNA | — | — | — | — | — | — | — | — |
| TAVNEOS | — | — | — | — | — | — | — | — |
| Ultra-Rare products | — | — | — | — | — | — | — | — |
| TEZSPIRE | — | — | — | — | — | — | — | — |
| Otezla | — | — | — | — | — | — | — | — |
| Enbrel | $5.43B | $5.97B | — | — | — | — | — | — |
| AMJEVITA/AMGEVITA | — | — | — | — | — | — | — | — |
| BLINCYTO | — | $115.0M | — | — | — | — | — | — |
| Vectibix | — | $611.0M | — | — | — | — | — | — |
| KYPROLIS | $835.0M | $692.0M | — | — | — | — | — | — |
| LUMAKRAS/LUMYKRAS | — | — | — | — | — | — | — | — |
| XGEVA | $1.58B | $1.53B | — | — | — | — | — | — |
| Nplate | — | $584.0M | — | — | — | — | — | — |
| IMDELLTRA | — | — | — | — | — | — | — | — |
| MVASI | — | — | — | — | — | — | — | — |
| EPOGEN | $1.10B | $1.28B | — | — | — | — | — | — |
| Aranesp | $2.05B | $2.09B | — | — | — | — | — | — |
| Parsabiv | — | — | — | — | — | — | — | — |
| Neulasta | $4.53B | $4.65B | — | — | — | — | — | — |
| NEUPOGEN | — | $765.0M | — | — | — | — | — | — |
| Sensipar/Mimpara | $1.72B | $1.58B | — | — | — | — | — | — |
| Other products | $2.58B | $250.0M | — | — | — | — | — | — |
| Other revenues | $1.05B | $1.10B | — | — | — | — | — | — |
| Cost of Revenue | $4.07B | $4.16B | $4.23B | $4.42B | $3.35B | $3.20B | $2.71B | — |
| Gross Profit | $18.78B | $18.83B | $17.44B | $15.64B | $15.33B | $14.07B | $12.87B | — |
| Gross Margin | 82.2% | 81.9% | 80.5% | 78.0% | 82.1% | 81.5% | 82.6% | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $4.87B | $5.06B | $4.85B | $4.70B | $5.18B | $4.81B | $4.50B | $3.98B |
| Operating Income | $9.97B | $9.79B | $8.47B | $6.19B | $5.87B | $5.58B | $4.31B | $5.55B |
| Operating Margin | 43.6% | 42.6% | 39.1% | 30.9% | 31.4% | 32.3% | 27.7% | 36.8% |
| Interest Expense | $1.30B | $1.26B | $1.10B | $1.07B | $1.02B | $1.05B | $610.0M | $604.0M |
| Pretax Income | $9.60B | $9.16B | $7.98B | $5.59B | $5.27B | $5.01B | $4.15B | $5.32B |
| Income Tax Expense | $7.62B | $1.44B | $1.04B | $427.0M | $184.0M | $664.0M | $467.0M | $690.0M |
| Net Income | $1.98B | $7.72B | $6.94B | $5.16B | $5.08B | $4.35B | $3.68B | $4.63B |
| Net Margin | 8.7% | 33.6% | 32.0% | 25.7% | 27.2% | 25.2% | 23.6% | 30.7% |
| EPS (Basic) | $2.71 | $10.32 | $9.15 | $6.80 | $6.75 | $5.61 | $4.07 | $4.82 |
| EPS (Diluted) | $2.69 | $10.24 | $9.06 | $6.70 | $6.64 | $5.52 | $4.04 | $4.79 |
| Shares Outstanding (Basic) | 731.0M | 748.0M | 758.0M | 759.0M | 753.0M | 775.0M | 905.0M | 960.0M |
| Shares Outstanding (Diluted) | 735.0M | 754.0M | 766.0M | 770.0M | 765.0M | 787.0M | 912.0M | 965.0M |
| Dividends Per Share | $4.77 | $4.15 | — | — | — | — | — | — |